Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dongchu Wang of Lu Daopei Hospital for an exclusive interview. He shared his insights into the current landscape of CD7 CAR-T therapy for T-cell malignancies, research on the association between cytokine levels and graft-versus-host disease (GVHD) following bridge-to-transplantation therapy, and future directions for combining CAR-T therapy with transplantation.

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Shu Yan of Hebei Yanda Lu Daopei Hospital for an exclusive interview. He shared his professional insights on the epidemiological characteristics of invasive fungal disease (IFD) after hematopoietic stem cell transplantation, comprehensive management pathways, and treatment optimization strategies.

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Jiujiang He of Hebei Yanda Lu Daopei Hospital for an exclusive interview. He shared his professional insights on the therapeutic role of venetoclax in acute myeloid leukemia (AML), challenges in real-world clinical practice, and future directions, providing perspectives and references for the standardized diagnosis and treatment of AML.

On August 21, 2026, the 14th Lu Daopei Hematology Forum was successfully held at the new campus of Hebei Yanda Lu Daopei Hospital. After 14 years of continuous development, the Lu Daopei Hematology Academic Conference has become an influential platform for academic exchange in the field of hematology in China, witnessing the evolution of hematologic disease diagnosis and treatment from accumulated clinical experience toward evidence-based innovation. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Xiaosu Zhou from the Beijing Lu Daopei Institute of Hematology to share the latest research findings on atypical acute promyelocytic leukemia (APL), focusing on its fusion gene landscape, underlying pathogenesis, and prospects for clinical translation.

As precision medicine continues to advance in hematologic malignancies, the clinical value of germline genetic factors is gradually extending beyond disease-risk assessment to influence treatment decision-making. For patients undergoing hematopoietic stem cell transplantation (HSCT), donor selection has traditionally focused on factors such as HLA matching, donor–recipient relationship, donor age, and overall health status. However, an increasingly important question is: Could the germline genetic backgrounds shared by or differing between donors and recipients also affect post-transplant disease control, infection risk, and long-term survival?

On August 25, 2026, Nature Reviews Gastroenterology & Hepatology (IF 57.5) published online a commentary titled "The International Chinese Young Scholars Alliance for the Study of the Liver: facilitating global collaboration," jointly completed by Xiaolong Qi (Zhongda Hospital Southeast University, China), Wenhao Li (Royal London Hospital, UK), Zhujun Cao (European Foundation for the Study of Chronic Liver Failure / Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China), Yee Hui Yeo (Cedars-Sinai Medical Center, Los Angeles, USA), Ying Shang (Karolinska Institutet, Solna, Sweden), and Kaina Chen (Singapore General Hospital, Singapore).

The 2026 European Society for Medical Oncology (ESMO) Congress will be held from October 23–27 in Madrid, Spain. As one of the most influential academic meetings in global oncology, ESMO attracts tens of thousands of leading experts each year and provides a platform for cross-border and multidisciplinary scientific exchange through a combination of online and in-person formats.

The 2025 European Society for Medical Oncology (ESMO) Congress is set to take place in Berlin, bringing together leading experts and cutting-edge research from across oncology. In hematology, several studies are attracting particular attention, spanning mechanisms of CAR-T resistance, innovative dual-target therapies, MRD-guided treatment discontinuation in multiple myeloma, and single-cell profiling. Together, these advances highlight the rapid evolution of hematologic malignancy research and the growing potential for more precise, individualized treatment strategies.

The 2025 European Society for Medical Oncology (ESMO) Congress is set to take place in Berlin, bringing together the latest advances and cutting-edge research in oncology. In hematology, several highly anticipated research directions are attracting attention, ranging from investigations into the mechanisms of CAR-T cell resistance and potential strategies to overcome this challenge, to innovative dual-target therapies that may offer more precise and effective treatment options. Other highlights include MRD-guided treatment discontinuation in multiple myeloma, which may help improve long-term survival and quality of life, as well as single-cell profiling studies providing new insights into the pathogenesis of hematologic malignancies. Together, these studies reflect the continued advancement of hematologic oncology and the emergence of new opportunities for more precise diagnosis and treatment.